Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 55Myelodysplastic Syndromes 32Leukemia 18Leukemia, Myelomonocytic, Chronic 11Congenital Abnormalities 5Recurrence 4Neoplasms 4Melanoma 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Anemia, Refractory 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytopenia 1Thrombocythemia, Essential 1Skin Neoplasms 1Sarcoma, Synovial 1Primary Myelofibrosis 1

Interventions

Azacitidine 2midostaurin 1Vorinostat 1Nivolumab 1Lenalidomide 1Injections 1Decitabine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × GATA2 Deficiency × Decitabine × Clear all
NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2/3 Completed
76 enrolled 16 charts
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡